Ads
related to: nintedanib for ipf 3 months download- Your Treatment Plan
Find Out If It Fits
in Your Plan
- Savings Info Available
Discover Potential Financial
Savings
- Prescription Savings
Financial Assistance Info
For Eligible Patients
- How It Helps
Discover How OFEV®
May Help Patients
- Your Treatment Plan
Search results
Results from the WOW.Com Content Network
Nintedanib, sold under the brand names Ofev and Vargatef, is an oral medication used for the treatment of idiopathic pulmonary fibrosis and along with other medications for some types of non-small-cell lung cancer.
[3] [12] A recent study from the US estimated the incidence of IPF to be between 6.8 and 16.3 per 100,000 persons. In the 27 European Union countries, a range of sources estimate an incidence of 4.6–7.4 people per 100,000 of the population, [ 73 ] [ 74 ] suggesting that approximately 30,000–35,000 new patients will be diagnosed with IPF ...
Ziritaxestat is a small-molecule, selective autotaxin inhibitor that was investigated as a potential treatment for idiopathic pulmonary fibrosis (IPF). [1] Initially showing promise in early-phase studies, ziritaxestat underwent evaluation in two large-scale phase 3 clinical trials, ISABELA 1 and ISABELA 2.
[1] [3] [6] But in most cases the cause is unknown (idiopathic pulmonary fibrosis). [1] [3] Diagnosis may be based on symptoms, medical imaging, lung biopsy, and lung function tests. [1] No cure exists and treatment options are limited. [1] Treatment is directed toward improving symptoms and may include oxygen therapy and pulmonary rehabilitation.
Since the medical term for conditions of unknown cause is "idiopathic", the clinical term for UIP of unknown cause is idiopathic pulmonary fibrosis (IPF). [2] Examples of known causes of UIP include connective tissue diseases (primarily rheumatoid arthritis ), drug toxicity, chronic hypersensitivity pneumonitis , asbestosis and Hermansky ...
Drug Manufacturer Indication Adagrasib: In combination with cetuximab for the treatment of adults with KRAS G12C mutated locally advanced or metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy [2]
The median survival in idiopathic pulmonary fibrosis is 3-3.5 years. In those who receive a lung transplant, the medial survival in idiopathic pulmonary fibrosis is 5.2 years, as compared to 6.7 years in those with other types of ILD. [8] ILD is associated with a 3-fold increased risk of lung cancer. [8]
The strategy of development of setanaxib was initially focused on the treatment of fibrosis and particularly idiopathic pulmonary fibrosis (IPF). Setanaxib obtained orphan drug designation from regulatory agencies in the US and EU in early 2010. [12] It was later granted FDA Fast Track Designation in PBC in August 2021. [13]
Ads
related to: nintedanib for ipf 3 months download